RVTY
Revvity
$99.04
▼ 1.0%Updated Today 7:15 PM ET
▲ Up 5.9% over the last 12 months
Market Cap
$11.16B
P/E
46.8x
Forward P/E (est.)
52.38x
ROE
3.3%
Revenue Growth
4.8%
EPS Growth
-10.7%
Profit Margin
8.3%
FCF Yield
5.1%
Debt / Equity
0.44x
ROIC
3.0%
Interest Coverage
7.17x
Current Ratio
1.72x
Dividend Yield
0.3%
Implied Growth (rev. DCF)
4.2%
Rating Score
33/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what RVTY's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. RVTY trades near $99.04, above its 50-day average ($95.29) and 200-day average ($95.47). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 44 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. RVTY's is $4.02 (~4.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month RVTY found buyers near $92.97 (support) and sellers near $106.21 (resistance); its 52-week range is $81.22–$118.30. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.6× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Revvity (RVTY) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $11.16B.
In its latest reported year it generated about $2.86B in revenue and $241.20M in net profit.
Our model rates RVTY Weak (33/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
1.8%
Revenue moved from $2.66B in 2021 to $2.86B in 2025, a 1.8% compound annual growth rate. The most recent year was roughly flat (4.8%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
54.3%
Operating Margin
12.5%
Net Margin
8.4%
ROE
3.3%
Revvity keeps about 8.3% of each sales dollar as net profit, with a 54.3% gross margin and 12.5% operating margin. Return on equity is 3.3% and return on invested capital about 3.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$3.90B
Net Debt
$3.04B
Net Debt / EBITDA
8.52x
Debt / Equity
0.44x
Leverage: debt-to-equity is 0.4x, and operating profit covers interest about 7.2x, with a current ratio of 1.7x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $3.90B of total debt against $860.32M of cash.
Operating CF
$582.93M
Free Cash Flow
$509.41M
FCF Margin
17.8%
In the latest year Revvity produced about $582.93M of operating cash flow and $509.41M of free cash flow after capital spending. That is a free-cash-flow yield of about 5.1% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
46.8x
P/S
3.98x
P/B
1.5x
EV / EBITDA
18.81x
RVTY trades at 46.8x trailing earnings (about 52.4x on estimated forward earnings), 4.0x sales, and 1.5x book value. Reverse-engineering today's price implies the market expects roughly 4.2% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How RVTY stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), RVTY ranks #52 of 59 by our overall rating. It trades at a premium versus the sector on earnings (46.8x P/E vs. 25.4x median) with a lower return on equity (3.3% vs. 14.9%) and slower revenue growth (4.8% vs. 7.9%).
P/E vs sector
46.8x
median 25.4x
ROE vs sector
3.3%
median 14.9%
Growth vs sector
4.8%
median 7.9%
Sector rank
#52
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$73.19 – $122.85
vs. $99.04 today · expected CAGR -6% – 4%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $3.00B | $3.15B | $3.31B | $3.47B | $3.65B |
| Net income | $239.91M | $251.90M | $264.50M | $277.72M | $291.61M |
| EPS | $2.15 | $2.26 | $2.37 | $2.49 | $2.61 |
| Share price (low) | $60.21 | $63.22 | $66.39 | $69.70 | $73.19 |
| Share price (high) | $101.07 | $106.13 | $111.43 | $117.00 | $122.85 |
| CAGR (low–high) | -39% / 2% | -20% / 4% | -12% / 4% | -8% / 4% | -6% / 4% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for RVTY:
- Healthy free-cash-flow yield (~5.1%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.4x) lowers risk.
The case against RVTY:
- A rich 46.8x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (33/100).
Valuation risk — at 46.8x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Revvity is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 46.8x earnings, which our model scores Weak (33/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.